Mutant HSCs appear to drive AML

These HSCs also appear to be a means of treatment resistance and may trigger relapse in patients with AML, investigators reported in Nature. “Our...

Conference Coverage

Lower-dose quizartinib diminishes QT events

Major finding: An increase in QTcF from baseline of more than 60 msec was seen in 19% of patients on quizartinib 60 mg and in 3% of those on 30 mg...


Brd4: Potential new target in AML

“The drug candidate not only displays remarkable anti-leukemia activity in aggressive disease models and against cells derived from patients with...